Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis (vol 80, pg 789, 2023)

被引：0
|
作者：
不详
机构：
来源：
JAMA NEUROLOGY | 2023年 / 80卷 / 10期
关键词：
D O I：
10.1001/jamaneurol.2023.2958
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1119 / 1119
页数：1
相关论文
共 50 条
  • [1] Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
    Roos, Izanne
    Hughes, Stella
    McDonnell, Gavin
    Malpas, Charles B.
    Sharmin, Sifat
    Boz, Cavit
    Alroughani, Raed
    Ozakbas, Serkan
    Buzzard, Katherine
    Skibina, Olga
    van der Walt, Anneke
    Butzkueven, Helmut
    Lechner-Scott, Jeannette
    Kuhle, Jens
    Terzi, Murat
    Laureys, Guy
    Van Hijfte, Liesbeth
    John, Nevin
    Grammond, Pierre
    Grand'Maison, Francois
    Soysal, Aysun
    Jensen, Ana Voldsgaard
    Rasmussen, Peter Vestergaard
    Svendsen, Kristina Bacher
    Barzinji, Ismael
    Nielsen, Helle Hvilsted
    Sejbaek, Tobias
    Prakash, Sivagini
    Stilund, Morten Leif Munding
    Weglewski, Arkadiusz
    Issa, Nadia Mubder
    Kant, Matthias
    Sellebjerg, Finn
    Gray, Orla
    Magyari, Melinda
    Kalincik, Tomas
    MSBase Study Grp
    Danish MS Registry Study Grp
    JAMA NEUROLOGY, 2023, 80 (08) : 789 - 797
  • [2] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [3] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [4] Rituximab in relapsing-remitting multiple sclerosis
    Schrijver, Hans M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645
  • [5] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Zhou, Hongyu
    Han, Wenjie
    Zhang, Shihong
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):
  • [6] A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis
    Roos, I.
    Hughes, S.
    MacDonnell, G.
    Boz, C.
    Alroughani, R.
    Ozakbas, S.
    Buzzard, K.
    Skibina, O.
    Van der Walt, A.
    Butzkueven, H.
    Lechner-Scott, J.
    Kuhle, J.
    Terzi, M.
    Laureys, G.
    Van Hijfte, L.
    John, N.
    Grammond, P.
    Grand'Maison, F.
    Soysal, A.
    Sellebjerg, F.
    Gray, O.
    Magyari, M.
    Kalincik, T.
    Msbase and Danish Sclerosis Registry Study Grp
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 951 - 953
  • [7] Cost-Utility Analysis Comparing Ocrelizumab vs Rituximab in the Treatment of Relapsing-Remitting Multiple Sclerosis: The Colombian Perspective
    Navarro, Cristian E.
    Betancur, John E.
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 83 - 91
  • [8] Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis
    Hartung, Hans-Peter
    Benedict, Ralph H. B.
    Berger, Thomas
    Bermel, Robert A.
    Brochet, Bruno
    Carroll, William M.
    Freedman, Mark S.
    Holmoy, Trygve
    Karabudak, Rana
    Nos, Carlos
    Patti, Francesco
    Perrin Ross, Amy
    Vanopdenbosch, Ludo
    Vollmer, Timothy
    Wuerfel, Jens
    Clinch, Susanne
    Kadner, Karen
    Kuenzel, Thomas
    Kulyk, Inessa
    Raposo, Catarina
    Thanei, Gian-Andrea
    Killestein, Joep
    NEUROLOGY, 2024, 103 (12)
  • [9] Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis (vol 15, 1480676, 2024)
    Rodriguez-Jorge, Fernando
    Fernandez-Velasco, Jose Ignacio
    Villarrubia, Noelia
    Gracia-Gil, Julia
    Fernandez, Eva
    Meca-Lallana, Virginia
    Diaz-Perez, Carolina
    de la Maza, Susana Sainz
    Pacheco, Eva Maria
    Quiroga, Ana
    Ramio-Torrenta, Lluis
    Martinez-Yelamos, Sergio
    Bau, Laura
    Monreal, Enric
    Lopez-Real, Ana
    Rodero-Romero, Alexander
    Borrega, Laura
    Diaz, Santiago
    Eguia, Pablo
    Espino, Mercedes
    Chico-Garcia, Juan Luis
    Barrero, Francisco Javier
    Martinez-Gines, Maria Luisa
    Garcia-Dominguez, Jose Manuel
    de la Fuente, Soraya
    Moreno, Irene
    Sainz-Amo, Raquel
    Mane-Martinez, M. Alba
    Caminero, Ana
    Castellanos-Pinedo, Fernando
    Lopez, Ana Gomez
    Labiano-Fontcuberta, Andres
    Ayuso, Lucia
    Abreu, Rossana
    Hernandez, Miguel angel
    Meca-Lallana, Jose
    Martin-Aguilar, Lorena
    Garcia, Alfonso Muriel
    Masjuan, Jaime
    Costa-Frossard, Lucienne
    Villar, Luisa Maria
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [10] Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis
    Roos, I.
    Sharmin, S.
    Ozakbas, S.
    Horakova, D.
    Havrdova, E. K.
    Boz, C.
    Alroughani, R.
    Patti, F.
    Terzi, M.
    Lechner-Scott, J.
    Izquierdo, G.
    Eichau, S.
    Grammond, P.
    Buzzard, K.
    Skibina, O.
    Prat, A.
    Girard, M.
    Duquette, P.
    Soysal, A.
    Grand'Maison, F.
    Kuhle, J.
    van der Walt, A.
    Butzkueven, H.
    Turkoglu, R.
    Butler, E.
    Laureys, G.
    van Hijfte, L.
    Shaygannejad, V.
    Yamout, B.
    Khoury, S.
    Prevost, J.
    Sidhom, Y.
    Gouider, R.
    Cartechini, E.
    Sanchez-Menoyo, J. L.
    Sa, M. Jose
    Macdonell, R.
    van Pesch, V.
    Ramo-Tello, C.
    McCombe, P.
    Willekens, B.
    Spitaleri, D.
    Ampapa, R.
    Al-Asmi, A.
    Slee, M.
    Besora, S.
    Malpas, C.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 778 - 780
12345